Houston Gilbert is Vice President of Biometrics at HI-Bio. Houston began his career at Genentech, where he focused on the delivery of targeted therapies and personalized health care. While at Genentech, he oversaw translational and early development oncology biostatistics, co-developed a personalized cancer vaccine with BioNTech, and participated in key regulatory interactions leading to the approval of FoundationOne CDx.

Before joining HI-Bio, Houston was Vice President, Biometrics and Data Management at Arcus Biosciences, where he represented Arcus in strategic co-development partnerships with Gilead, AstraZeneca and other companies. Previously, Houston led biostatistics efforts at Bellicum Pharmaceuticals developing hematopoietic stem cell transplant and solid tumor CAR-T assets. Houston has a BS in Biology from Harvey Mudd College and MPH and PhD degrees in Biostatistics from the University of California, Berkeley.